Parkinson's Disease

Parkinson's disease (PD) is the second most common neurodegenerative disorder in the United States, affecting approximately 1.2 million Americans — a number projected to reach 1.6 million by 2037. It is a chronic, progressive disease of the nervous system that erodes motor control, cognitive function, and independence over time.

Unlike many conditions, Parkinson's has no cure and no proven treatment that slows its progression. Current therapies manage symptoms effectively for years — even decades — but the disease ultimately advances. That progression drives increasing care needs, rising medical costs, and heavy caregiver burden that few families fully anticipate.

This white paper is designed to give patients, family members, and caregivers a clear, honest picture of Parkinson's disease — from diagnosis through advanced stages. It covers:

• What Parkinson's is and how it progresses
• How it is diagnosed and staged
• Every major current maintenance medication and what it does
• The most promising clinical trials underway in 2026
• The real cost of care at each stage
• Long-term care planning options — private pay, Medicaid, LTC insurance, and annuities
• The critical importance of early planning

What Is Parkinson's Disease?

Parkinson's disease is a progressive neurological disorder caused by the loss of dopamine-producing neurons in a region of the brain called the substantia nigra. Dopamine is the chemical messenger that coordinates smooth, controlled movement. As these neurons die, dopamine levels drop, and the brain's ability to regulate movement deteriorates.

The disease was first described by English physician Dr. James Parkinson in 1817 in his landmark Essay on the Shaking Palsy. Today, more than 200 years later, it remains one of medicine's most complex challenges — treatable but not curable.

How Common Is Parkinson's Disease?

What Causes Parkinson's Disease?

The exact cause of Parkinson's remains unknown in most cases. Research points to a combination of genetic and environmental factors:

Genetic Factors

• Mutations in genes such as LRRK2, PINK1, PRKN, SNCA, and GBA increase risk
• About 10–15% of PD cases are directly linked to an inherited gene mutation
• The LRRK2 mutation is the most common known genetic cause, found in 1–2% of all PD patients and up to 20% of Ashkenazi Jewish patients

Environmental Factors

• Long-term exposure to pesticides, herbicides, and industrial chemicals
• Head trauma history
• Rural living and well water consumption (possibly linked to pesticide exposure)
• Manganese or other heavy metal exposure in occupational settings

The Role of Alpha-Synuclein

A protein called alpha-synuclein plays a central role in most forms of PD. In people with Parkinson's, alpha-synuclein misfolds and clumps together, forming toxic aggregates called Lewy bodies inside neurons. These Lewy bodies spread through the brain, damaging dopamine-producing cells. Alpha-synuclein is now a primary target of the most promising new clinical trials.

Symptoms of Parkinson's Disease

Parkinson's symptoms are divided into two categories: motor symptoms (affecting movement) and non-motor symptoms (affecting everything else). Both categories worsen over time and eventually drive care needs.

Motor Symptoms (The Classic Four)

• Tremor — Rhythmic shaking, most commonly in the hands at rest; the hallmark symptom
• Bradykinesia — Slowness of movement; reduced arm swing, smaller steps, masked facial expression
• Rigidity — Muscle stiffness and resistance to movement, often causing pain
• Postural instability — Loss of balance and coordination; major fall risk in later stages

Non-Motor Symptoms (Often Underestimated)

• Cognitive decline and dementia (affects up to 80% of patients over time)
• Depression and anxiety (occur in 40–60% of patients)
• Sleep disorders, including REM sleep behavior disorder (acting out dreams)
• Autonomic dysfunction: constipation, urinary problems, low blood pressure on standing
• Loss of smell (often one of the earliest signs, occurring years before motor symptoms)
• Fatigue and pain
• Speech and swallowing difficulties

How Does Parkinson's Progress? The Five Stages

On average, a person lives 10–20 years after a Parkinson's diagnosis. The rate of progression varies widely — some individuals remain at Stage 2 for many years; others progress more rapidly. The uncertainty of progression makes early financial and care planning especially critical.

There is no definitive blood test or brain scan that confirms Parkinson's disease with certainty. Diagnosis is based on a neurological examination and medical history. A movement disorder specialist — a neurologist with specialized training in Parkinson's — provides the most accurate diagnosis.

Diagnostic Criteria

Doctors use the United Kingdom Parkinson's Disease Society Brain Bank Criteria. A diagnosis requires:

• Bradykinesia (slowness of movement) — required in all cases
• Plus at least one of: muscle rigidity, resting tremor, or postural instability
• Absence of features that suggest another condition (called 'red flags')
• At least three 'supporting criteria' such as excellent response to levodopa, rest tremor, and progressive course

Diagnostic Tools

• Neurological examination — The primary diagnostic tool
• DaTscan (Dopamine Transporter Scan) — Nuclear imaging that shows dopamine activity in the brain; helps distinguish PD from similar conditions
• MRI and CT scans — Used to rule out other causes such as stroke or tumors
• Genetic testing — Recommended for patients with family history or early onset (before age 50)
• Skin biopsy for alpha-synuclein — A newer test now available that detects misfolded alpha-synuclein in nerve fibers of the skin; being adopted as an objective biomarker

As of 2026, there are no medications proven to slow, stop, or reverse Parkinson's disease progression. All approved treatments are symptomatic — they manage the effects of dopamine deficiency but do not address the underlying disease process. However, these medications are highly effective at controlling symptoms, often for many years.

Class 1: Levodopa / Carbidopa — The Gold Standard

Levodopa, first introduced in the 1960s, remains the most effective medication for Parkinson's disease after more than 60 years. It is a precursor to dopamine that crosses the blood-brain barrier and is converted into dopamine in the brain. Carbidopa is always combined with levodopa to prevent it from being metabolized before reaching the brain, reducing side effects.

The 'On/Off' Problem

With long-term use (typically 5–10 years), levodopa's effectiveness becomes unpredictable. Patients experience 'on' periods when the medication works and 'off' periods when it wears off and symptoms return. Managing these fluctuations is a central challenge of advanced Parkinson's care. Several newer formulations and delivery systems address this problem.

Class 2: Dopamine Agonists

Dopamine agonists mimic the effect of dopamine in the brain by directly stimulating dopamine receptors. They are less powerful than levodopa but cause fewer motor fluctuations. Often used as first-line therapy in younger patients or as add-on therapy to levodopa. Side effects can include impulse control disorders (compulsive gambling, shopping, or eating), hallucinations, and excessive daytime sleepiness.

Class 3: MAO-B Inhibitors

Monoamine oxidase-B (MAO-B) inhibitors block an enzyme that breaks down dopamine in the brain, extending the effect of naturally produced and supplemental dopamine. Often used as initial monotherapy in early PD or as add-on therapy.

Class 4: COMT Inhibitors

Catechol-O-methyltransferase (COMT) inhibitors block another enzyme that breaks down levodopa and dopamine, extending the duration of each levodopa dose. Used exclusively as add-on therapy to levodopa to reduce 'wearing off.'

Class 5: Amantadine

Amantadine was originally an antiviral drug discovered to improve PD symptoms. Its mechanism is complex — it blocks glutamate receptors and has mild dopaminergic effects. It is primarily used to reduce levodopa-induced dyskinesia (involuntary movements), a major quality-of-life problem in advanced PD.

Class 6: Adenosine A2A Receptor Antagonist

Class 7: Anticholinergics (Older, Limited Use)

Anticholinergic medications were among the earliest PD treatments. They block acetylcholine to rebalance it against dopamine. Used rarely today — primarily for younger patients with predominant tremor — because they cause confusion, memory problems, and constipation, making them risky for older adults.

• Trihexyphenidyl (Artane) — Still used selectively for tremor in younger patients
• Benztropine (Cogentin) — Similar use; also treats drug-induced parkinsonism

Surgical Treatment: Deep Brain Stimulation (DBS)

Deep Brain Stimulation is not a medication, but it is a well-established treatment for appropriate candidates with advanced PD and medication-refractory motor fluctuations. Electrodes are surgically implanted in specific brain targets (subthalamic nucleus or globus pallidus) and connected to a pacemaker-like device in the chest that delivers continuous electrical stimulation.

• Reduces tremor, rigidity, and OFF time significantly in well-selected candidates
• Allows most patients to reduce levodopa dose, reducing dyskinesia
• Does not slow disease progression or treat non-motor symptoms
• Best candidates: Younger patients with good cognitive function and clear levodopa benefit
• Adaptive DBS (aDBS) received FDA approval in early 2025 — a 'closed loop' system that senses brain activity in real time and automatically adjusts stimulation (Medtronic Percept with BrainSense)

Focused Ultrasound

FDA-approved MRI-guided focused ultrasound (MRgFUS) uses concentrated ultrasound energy to create a precise lesion in a brain target — noninvasively, with no incision. Approved for essential tremor (2016) and unilateral PD tremor (2021). It provides immediate, dramatic tremor relief on the treated side but cannot address other symptoms or be repeated. Research into bilateral treatment is ongoing.

2025–2026 represents the most active period in the history of Parkinson's research. For the first time, multiple trials are testing drugs that may actually slow or stop the disease — not just manage its symptoms. These are called disease-modifying therapies (DMTs). No DMT has yet been proven effective, but several are showing strong signals.

Category A: Targeting Alpha-Synuclein (The Root Cause)

Alpha-synuclein is the protein that misfolds and aggregates (clumps) in Parkinson's neurons. Clearing or preventing these aggregates is considered the most direct way to slow or stop the disease. Multiple approaches are being tested simultaneously.

Prasinezumab (Roche / Prothena)

• Type: Monoclonal antibody (infusion) targeting and clearing aggregated alpha-synuclein
• Trial: Phase 3 planned after promising Phase 2b (PADOVA) results showing slower progression in patients on stable levodopa treatment
• Status: Phase 3 trial design underway; Stanford is expected to be a site
• Why it matters: First antibody-based alpha-synuclein therapy to show a statistically significant signal in a Phase 2 subgroup — a meaningful first for the field

ABL301 (AbbVie)

• Type: Monoclonal antibody with a 'Trojan horse' mechanism to cross the blood-brain barrier more effectively than prior antibodies
• Trial: Phase 1 completed (safe and well-tolerated); Phase 2 in planning
• Why it matters: Better brain penetration has been the limitation of previous anti-synuclein antibodies; ABL301 is designed to solve that problem

ACI-7104.056 — The Alpha-Synuclein Vaccine (AC Immune)

• Type: First-ever active vaccine against alpha-synuclein — stimulates the patient's own immune system to generate antibodies
• Trial: Phase 2 (VacSyn trial); interim data showed clear antibody formation and good tolerability
• Why it matters: A vaccine approach would be far simpler and cheaper than regular infusions; could be given once or twice a year

Category B: LRRK2 Inhibitors

LRRK2 (Leucine-rich repeat kinase 2) is a protein that becomes hyperactive in some forms of Parkinson's, damaging dopamine neurons. Blocking LRRK2 is most relevant for patients with LRRK2 mutations — but researchers believe it may benefit all patients since LRRK2 is elevated in many PD cases.

BIIB122 / DNL151 (Biogen / Denali Therapeutics)

• Type: Small molecule oral LRRK2 inhibitor
• Trial: Phase 2b (LUMA trial); results expected in late 2026
• Enrolling: Patients with and without LRRK2 mutations at multiple sites including UCSF
• Why it matters: If effective across all PD patients — not just LRRK2 mutation carriers — this would be a major breakthrough

ARV-102 (Arvinas)

• Type: Protein degrader (PROTAC) targeting LRRK2 — rather than blocking it, this approach degrades the protein entirely
• Trial: Phase 1/2 early results showed safe brain penetration and reduction in LRRK2 protein levels
• Why it matters: Protein degradation is a more complete approach than inhibition; early data is promising

Category C: Targeting Neuroinflammation

Chronic low-level inflammation in the brain accelerates neuron death in Parkinson's. Multiple trials are testing anti-inflammatory approaches.

BHV-8000 (Biohaven)

• Type: Oral drug inhibiting TYK2 and JAK1 enzymes to reduce brain inflammation
• Trial: Phase 2/3 enrolling up to 550 patients aged 40–85 with early-stage PD (diagnosed within 2 years)
• Duration: 48 weeks; primary goal is to slow functional decline
• Why it matters: Large trial with broad enrollment criteria; if positive, could apply to many patients

VENT-02 (Ventus Therapeutics)

• Type: Oral drug inhibiting the NLRP3 inflammasome — a key driver of brain inflammation in PD
• Trial: Phase 2a; first patient dosed; actively enrolling ~30 participants with mild to moderate PD
• Data expected: Late 2025 / early 2026

Dapansutrile — DAPA-PD Trial

• Type: Anti-inflammatory drug targeting NLRP3 inflammasome (different approach from VENT-02)
• Trial: Phase 2; recruitment beginning early 2026 (Cure Parkinson's / Van Andel Institute)
• Rationale: Reduces brain inflammation to protect remaining dopamine neurons

Category D: Gene Therapy

Gene therapy delivers a working copy of a gene directly into brain cells using a viral vector. Unlike medications that must be taken daily, gene therapy potentially requires only a single treatment. Several approaches are in development.

AB-1005 / AAV-GDNF (AskBio / Bayer) — REGENERATE-PD Trial

• Type: Gene therapy delivering the GDNF gene (a powerful neurotrophic factor) into the brain to protect and restore dopamine neurons
• FDA Status: Received FDA Regenerative Medicine Advanced Therapy (RMAT) designation in February 2025 — a fast-track designation for promising therapies
• Trial: Phase 2 (REGENERATE-PD) — randomized, double-blind, sham surgery-controlled; ~87 patients with moderate PD; measuring motor function changes over 18 months
• Why it matters: GDNF is one of the most potent known factors for dopamine neuron survival; delivering it directly to the brain via a single surgery could provide lasting benefit

ISM8969 (Insilico Medicine) — AI-Designed Therapy

• Type: Oral anti-inflammatory therapy designed entirely by artificial intelligence — first AI-developed PD drug to reach human trials
• Status: FDA application (IND) filed late 2025 to begin Phase 1 human trials
• Mechanism: Designed to block brain inflammation linked to PD progression
• Why it matters: Represents a new era of AI-driven drug discovery that could dramatically accelerate development timelines

Category E: Stem Cell Therapies

Stem cell therapies aim to physically replace the dopamine-producing neurons that have died — rebuilding the brain's capacity rather than just compensating for its loss. This approach is the most complex and is still in early-stage clinical testing.

Bemdaneprocel (BlueRock Therapeutics / Bayer)

• Type: Off-the-shelf allogeneic dopaminergic neuron precursors derived from human embryonic stem cells
• Phase 1 result: Safe and well-tolerated; PET scan confirmed transplanted cells survived; high-dose patients gained 2.7 additional hours of ON time per day
• Trial: Phase 3 (exPDite-2) — randomized, double-blind, sham surgery-controlled; ~102 participants; first patient treated September 2025
• Why it matters: If the cells survive, integrate, and produce dopamine reliably, this could offer sustained years-long benefit from a single surgery

ANPD001 (Aspen Neuroscience)

• Type: Personalized, patient-specific (autologous) dopamine neuron precursors grown from the patient's own skin cells — no need for immunosuppressants
• Trial: Phase 1/2a (ASPIRO); third cohort now receiving treatment
• Advantage: Because cells come from the patient's own body, immune rejection is not a concern — a significant challenge with other cell therapies

Category F: Established Drugs Being Repurposed

Several well-known, already-approved drugs are being tested as potential disease-modifiers for Parkinson's — a faster, lower-cost pathway to new treatments.

Ambroxol — ASPro-PD Trial (Phase 3)

• What it is: An over-the-counter cough medication used for decades in Europe
• Mechanism: Increases GCase enzyme activity in brain cells — helping clear the protein waste (including alpha-synuclein) that accumulates in PD neurons
• Trial: Phase 3 (ASPro-PD); 330 patients; ambroxol vs. placebo for 2 years; comparing quality of life and movement; especially relevant for GBA1 mutation carriers
• Why it matters: If effective, this is an inexpensive, widely available drug that could be prescribed quickly

Risvodeninib (Sun Pharma / TransThera) — c-Abl Kinase Inhibitor

• Type: Oral capsule blocking c-Abl kinase, an enzyme that damages dopamine neurons when overactive
• Phase 2 result: Significant improvement in MDS-UPDRS symptom score and daily activities vs. placebo — one of the most encouraging Phase 2 results in recent years
• Status: Phase 3 design being planned with FDA input
• Why it matters: The Phase 2 result was clinically meaningful — patients were measurably better. Phase 3 will confirm or refute this finding

Category G: New Symptomatic Therapies (Not Disease-Modifying)

Several new drugs do not slow the disease but significantly improve quality of life for patients with advanced symptoms.

Tavapadon (AbbVie) — Under FDA Review 2026

• Type: Once-daily oral dopamine D1/D5 receptor agonist — novel mechanism vs. existing agonists
• Trials: Three Phase 3 trials (TEMPO program) all showed significant improvement in motor symptoms
• Key result: In advanced PD as add-on to levodopa, patients gained 1.1 extra hours of ON time per day without troublesome dyskinesia
• Status: New Drug Application submitted to FDA September 2025; decision expected in 2026
• Why it matters: If approved, would be the first once-daily oral dopamine agonist that selectively targets D1/D5 receptors — a new option for motor fluctuations

Solengepras (Cerevel/AbbVie) — ARISE Trial (Phase 3)

• Type: Non-dopaminergic oral drug targeting GPR6 receptor in the brain to rebalance motor circuits
• Trial: Phase 3 (ARISE) — adjunctive treatment for motor fluctuations; top-line data expected H1 2026
• Why it matters: Different mechanism from all existing PD drugs; could work in patients who do not tolerate dopaminergic side effects

The EJS ACT-PD — World's Largest Parkinson's Trial

Trial Summary Table

The financial impact of Parkinson's disease is severe and often underestimated. According to a March 2026 report from the Michael J. Fox Foundation and the Parkinson's Foundation, the total U.S. cost of Parkinson's disease in 2024 was $82.2 billion — and it is projected to exceed $112 billion by 2045.

Cost of Care by Stage and Setting

What Medicare Covers — and What It Does Not

• Medicare DOES cover: Physician visits, hospitalizations, medications (Part D), physical therapy, occupational therapy, speech therapy, home health visits (when skilled care is needed), and hospice
• Medicare does NOT cover: Custodial care — meaning help with bathing, dressing, eating, and mobility when no skilled nursing is needed. This is the care most Parkinson's patients need for the longest time.
• Medicare limits: Covers only short-term skilled nursing care after hospitalization (up to 100 days; full coverage for only 20 days). Does NOT pay for long-term nursing home stays.

The gap between what Medicare covers and what Parkinson's care actually costs must be filled by some combination of personal resources, insurance, or government assistance. The four primary options are:

Option 1: Private Pay (Personal Savings and Assets)

Many families rely on personal savings, retirement accounts, investments, and home equity to pay for care. This approach gives the most flexibility and choice in care settings, but it carries significant risk:

• A spouse or partner can be left financially vulnerable if assets are depleted
• Average nursing home costs of $90,000–$110,000/year can exhaust even significant savings within 5–10 years
• Home equity — often a family's largest asset — may need to be liquidated
• Best suited for individuals with $1.5 million or more in liquid assets

Option 2: Medicaid

Medicaid is the primary government payer for long-term nursing home care in the United States. Unlike Medicare, Medicaid does cover custodial care — but only after a person has spent down virtually all personal assets to qualify.

Medicaid Qualification (General Rules — Varies by State)

• Single individuals: Must have $2,000 or less in countable assets (Florida) to qualify
• Married couples: The community spouse (at home) may keep a portion of assets under Community Spouse Resource Protection rules — typically $30,000–$148,620 (2026 figures)
• Income rules vary significantly by state — some states are 'income cap' states (like Florida); others allow a Qualified Income Trust (Miller Trust)
• Look-back period: Medicaid reviews 5 years of asset transfers; gifts or transfers made within 5 years can trigger a disqualification period

Option 3: Traditional Long-Term Care Insurance (LTCI)

Long-term care insurance was designed specifically to pay for the custodial care that Medicare does not cover. A policy purchased before diagnosis provides a defined benefit — typically $150–$300/day — for care in a nursing home, assisted living facility, or at home.

Key Features

• Benefit triggers: Benefits are paid when the insured cannot perform 2 of 6 Activities of Daily Living (bathing, dressing, eating, toileting, transferring, continence) OR has cognitive impairment
• Parkinson's patients will typically qualify for benefits at Stage 3–4 — when balance, rigidity, and motor control significantly impair independence
• Coverage options: Home care, adult day care, assisted living, memory care, skilled nursing
• Inflation protection: A critical feature — care costs rise 3–5% annually; a policy without inflation protection loses real value over a 10–15 year horizon

Important Limitations

• Must be purchased before diagnosis — a Parkinson's diagnosis makes an individual uninsurable
• Ideal purchase window: Ages 55–65, in good health
• Annual premiums typically range from $2,000–$5,000+/year depending on age, benefit, and inflation option
• Premiums are not guaranteed — carriers can (and have) raised premiums on existing policyholders

Option 4: Long-Term Care Annuities and Hybrid Products

A growing category of financial products combines long-term care benefits with other financial vehicles:

Hybrid Life/LTC Policies

• Combine life insurance with a long-term care benefit rider
• Funded with a single premium or limited payments; premiums guaranteed not to increase
• If LTC benefits are not used, the death benefit passes to heirs
• Available from carriers such as Lincoln Financial, Nationwide, OneAmerica, Securian
• Advantage: Premium certainty; no 'use it or lose it' concern

LTC Annuities (Asset-Based LTC)

• A lump sum is deposited into an annuity; the carrier provides a multiple of the deposit (typically 2x–3x) available for long-term care expenses
• Can be funded with existing IRA, 401(k), or non-qualified assets
• Benefits are tax-free when used for qualified long-term care
• Provides guaranteed access to care funds without the premium payment concerns of traditional LTCI

The Case for Early Planning — A Timeline

Parkinson's disease is a family disease. As symptoms progress, family members — most often spouses and adult children — take on increasing caregiving responsibilities. The physical, emotional, and financial toll on caregivers is severe and often underrecognized.

What Caregivers Need to Know

• Caregiver burnout is not a sign of failure — it is a predictable outcome of an impossible burden sustained too long without support
• Respite care — temporary relief for caregivers — is covered by some LTC policies and some Medicaid waiver programs
• Adult day programs provide structured daytime care for PD patients while caregivers continue to work or recover
• Home health aides — whether paid by insurance or privately — dramatically reduce caregiver strain and delay nursing home placement
• Support groups for both patients and caregivers are available through the Parkinson's Foundation (parkinson.org) and local hospital systems

If you or a loved one has been diagnosed with Parkinson's disease, or if you are concerned about future risk, the following steps can protect your family:

1Connect with a Movement Disorder Specialist

A neurologist who specializes in Parkinson's and movement disorders will provide the most accurate diagnosis, the most current medication management, and can refer you to clinical trials. The Parkinson's Foundation offers a helpline and referral service: 1-800-4PD-INFO.

2Consult an Elder Law Attorney

An elder law attorney who specializes in Medicaid planning can evaluate your current financial situation and develop a strategy to protect assets — while there is still time. Even in early or mid-stage disease, legal planning options exist that can make a profound difference.

3Review Long-Term Care Insurance Options

If you or a family member does not yet have a diagnosis — or have a very recent early-stage diagnosis — a specialized long-term care insurance advisor can evaluate what coverage options remain available. Waiting even 6–12 months can eliminate remaining options.

4Explore Clinical Trials

Clinical trials offer access to potential breakthrough therapies — often at no cost — while contributing to research that benefits all Parkinson's patients. The Michael J. Fox Foundation's Fox Trial Finder at foxtrialfinder.org is the best starting point.

5Build Your Support Network

Contact the Parkinson's Foundation at parkinson.org for local support groups, care center referrals, and caregiver resources. Connection with others facing the same journey is consistently cited by patients and families as one of the most valuable resources available.